ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

CEO Bets Big as Andreessen Trims Samsara

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Summit Therapeutics CEO Robert Duggan filed a $50 million personal stock purchase on June 12. He bought 3.81 million shares at $13.12. The same week, Summit's CFO Manmeet Soni and President Maky Zanganeh also filed buys. Three top executives stepping in at the same time is a strong signal of internal confidence in the biotech firm's pipeline.

On the selling side, tech venture legend Marc Andreessen filed a wave of Samsara disposals this week. Filings show he sold over $85 million worth of shares between June 8 and June 12 across multiple tranches. All trades were done at prices between $32 and $35. Andreessen sits on Samsara's board as a Director.

NVIDIA also saw insider selling. Director Mark Stevens filed $111 million in sales on June 2. A second filing followed two days later for another $22 million. NVIDIA has risen sharply this year, so profit-taking from insiders is not unusual.

On the buying side, activist hedge fund Trian Partners — tied to board member Edward Garden — filed a $13 million purchase in Fortune Brands Innovations on June 10, signalling continued activist pressure on the home products maker.

This article is for informational purposes only and does not constitute financial advice.

Stocks in this article

How this article was generated

Generated
17 Jun 2026, 12:11
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.